Poland· PL-100482866
Symex
A exemestane product containing exemestanum, registered in Poland by Farmak International Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Exemestane is registered in 17 of 19 countries.
Countries holding a registration under ATC L02BG06 (exemestane), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Exemestane · ATC L02BG06
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of exemestane costs, country by country.
Normalised to the WHO defined daily dose (25 mg), the median price runs from $1.43 in France to $3.32 in Switzerland — a ×2.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Exemestane · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$3.32
- IT Italy$2.46
- FR France$1.43
The record
At a glance
URPL (Poland)- Active substance
- Exemestanum
- Manufacturer
- Farmak International Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- L02BG06
- ATC class
- Exemestane
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 8
1 priced- gtin0590570107035030 szt.PLN 76.51
- gtin05905701070329
- gtin05905701070336
- gtin05905701070343
- gtin05905701070367
- gtin05905701070374
- gtin05905701070381
- gtin05905701070398
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
236 interactions on record for exemestane.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Exemestane · interactions on record
236 records
- 1 severe
- 83 moderate
- 152 info
Most severe, free to view
- ThalidomideL04AX02severe
- TroglitazoneA10BG01moderate
- SulfinpyrazonB01AC12moderate
- FostamatinibB02BX09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Exemestane in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAROMASINPfizer, spol. s r.o., Praha
- SpainEXEMESTANO ACCORD 25 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- FranceEXEMESTANE ACCORD 25 mg, comprimé pelliculéACCORD HEALTHCARE FRANCE
- ItalyAROMASINPFIZER ITALIA S.R.L.
- NetherlandsExemestaan 25 mg Teva, filmomhulde tablettenTeva Nederland B.V.
- FinlandExemestan Ratiopharmratiopharm GmbH
- BelgiumExemchanelle Mylan 25 mgViatris GX
- SwedenExemestan Actavis 25 mg Filmdragerad tablettActavis Group PTC ehf.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Aromasin, Exemestan Accord
- Belgium · Aromasin, Exemestan Sandoz
- Bulgaria · Аромазин, Екземегратис
- Cyprus · Exedral
- Czechia · Aromasin, Astexana
- Germany · Aromasin, Exemestan 1 A Pharma
- Denmark · Aromasin, Exemestan Accord
- Estonia · Aromasin, Exemestane Accord
- Spain · Aromasil, Exemestano Aurovitas
- Finland · Aromasin, Exemestan Pfizer
- France · Aromasine, Exemestane Accord
- United Kingdom (Northern Ireland) · Aromasin, Exemestane
- Greece · Aromaplex, Aromasin
- Croatia · Aromasin, Eksemestan Jgl
- Hungary · Aromasin, Exemestane Pharmacenter
- Ireland · Aromasin, Exemestane Accord
- Iceland · Aromasin, Exemestan Actavis
- Italy · Aromasin, Axelta
- Lithuania · Aromasin, Exemestane Accord
- Luxembourg · Aromasin, Exemestan Ratiopharm
- Latvia · Exemestane Accord, Exemestane Sanoswiss
- Malta · Aromasin, Exedral 25
- Netherlands · Aromasin, Exemestaan Accord
- Norway · Aromasin, Exemestan Sandoz
- Portugal · Aromasin, Exemestano Accord
- Romania · Aromasin, Exemestan Accord
- Sweden · Exemestan Actavis, Exemestan Sandoz
- Slovenia · Aromasin
- Slovakia · Aromasin, Astexana
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c35b1cab-f115-441a-a5d2-6210b50e91f1 GET /v1/drugs/c35b1cab-f115-441a-a5d2-6210b50e91f1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "25 mg",
"packaging": "05905701070329 ¦ Rp ¦ 157310\n10 tabl.\n05905701070336 ¦ Rp ¦ 157311\n15 tabl.\n05905701070343 ¦ Rp ¦ 157312\n20 tabl.\n05905701070350 ¦ Rp ¦ 157313\n30 tabl.\n05905701070367 ¦ Rp ¦ 157314\n90 tabl.\n05905701070374 ¦ Rp ¦ 157315\n100 tabl.\n05905701070381 ¦ Rp ¦ 157316\n105 tabl.\n05905701070398 ¦ Rp ¦ 157317\n120 tabl.",
"substance": "Exemestanum 25 mg",
"common_name": "Exemestanum",
"pl_product_id": "100482866",
"pozwolenie_nr": "28558",
"auth_procedure": "DCP",
"authorisation_validity": "2029-08-12"
}See everything about exemestane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.